Expanding the universe of new treatments for patients

Arrakis Therapeutics Announces Presentations at Upcoming Spring Scientific Meetings

Waltham, Mass., March 20, 2023 – Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that the company will participate in six upcoming scientific conferences. The presentations will describe how Arrakis’ platform uses the principles of modern structure-based drug design to discover RNA-targeted small molecules (rSMs) based on the company’s pioneering understanding of the relationships among RNA sequences, the two- and three-dimensional structures they form, and their functions. This is now enabling Arrakis to build a powerful drug discovery foundation for selecting and optimizing rSM drug candidates that bind to RNA.

Details of the Arrakis presentations are as follows:

American Chemical Society National Meeting, Indianapolis, IN
Presentation title: Drugging RNA Structures with Drug-like Small Molecules
Date: Monday, March 27
Presenter: Jennifer Petter, PhD, Founder & Chief Innovation Officer

Drug Discovery Chemistry Conference, San Diego, CA
Presentation title:  Discovery of RNA-Targeted Small Molecule Therapeutics
Presenter: Kathleen McGinness, PhD, Vice President, Platform Biology
Presentation title:  Improving Machine Learning Predictions
Presenter: Anton Filikov, PhD, Associate Director/Principal Scientist, Computational Chemistry
Dates:  Tues, April 11 – Wed, April 12

Lund Spring Symposium, Lund, Sweden
Presentation Title: Targeting RNA with Small Molecules Using Structure-based Drug Design
Date: Friday, May 26
Presenter: Jennifer Petter, PhD, Founder & Chief Innovation Officer

Gordon Research Conferences Bioorganic Chemistry, Andover, NH
Presentation Title: A Structure-Based Approach to Drugging RNA with Small Molecules
Date: Monday, June 12
Time: 11:15 a.m. ET
Presenter: Jennifer Petter, PhD, Founder & Chief Innovation Officer

Cold Spring Harbor Asia, Awaji, Japan
Presentation Title: High Throughput Discovery of Ligandable RNA Structures in the Human Transcriptome
Date: Thursday, June 22
Presenter: Lee E. Vandivier, PhD, Scientist II, Computational Biology

Empowering Women in Organic Chemistry, Thousand Oaks, CA
Presentation Title: A Structure-based Approach to RNA-targeted Small Molecules
Date: Friday, June 23
Presenter: Jennifer Petter, PhD, Founder & Chief Innovation Officer

About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit www.arrakistx.com and engage with us on Twitter @ArrakisTx or on LinkedIn.